Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease

Keyphrases

• Crohn's Disease 100%
• Randomized Controlled Trial 100%
• Clarithromycin 100%
• Ethambutol 100%
• Lactulose Hydrogen Breath Test 50%
• Harvey-Bradshaw Index 50%
• Placebo 33%
• Intestinal Permeability 33%
• Placebo Groups 33%
• Disease Location 33%
• Mannitol 16%
• Disease Severity 16%
• High Risk 16%
• Relapse Risk 16%
• Antimycobacterial Activity 16%
• Treatment Group 16%
• Disease Duration 16%
• Twice Daily 16%
• Intestinal Injury 16%
• Lactulose 16%
• Disease Activity 16%
• Active Disease 16%
• 12-month Follow-up 16%
• Drug Groups 16%
• Complication Severity 16%
• Mycobacterial Infection 16%
• Standard Medical Therapy 16%
• Permeability Test 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Crohn's Disease 100%
• Randomized Controlled Trial 100%
• Clarithromycin 100%
• Ethambutol 100%
• Placebo 66%
• Mannitol 66%
• Lactulose 66%
• Disease 50%
• Intestinal Permeability 33%
• Infection 16%
• Combination Therapy 16%
• Intestine Injury 16%
• Disease Severity 16%
• Disease Activity 16%
• Antimycobacterial 16%